Home  /  Resource Library  /  Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma

Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma

Results of a study examining copanlisib combined with chemoimmunotherapy for treatment of relapsed indolent lymphomas.